Franklin Templeton, Inc. filed Amendment No. 4 to Schedule 13G with the SEC on October 26, 2026, disclosing beneficial ownership of 1,704,550 shares of Contineum Therapeutics, Inc. Class A Common Stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Franklin Templeton, Inc. and related filers reported 1,704,550 shares of Contineum Therapeutics Class A Common Stock, representing 5.2% of the class.
  • Sole voting and dispositive power: According to the filing, Franklin Advisers, Inc. holds sole voting power and sole dispositive power over all 1,704,550 shares; Franklin Templeton, Inc., Charles B. Johnson, and Rupert H. Johnson, Jr. each report 0 shares of sole voting or dispositive power.
  • Triggering event date: The date of event requiring the filing was September 30, 2026.
  • Name change noted: The filing states that effective August 17, 2026, Franklin Resources, Inc. was renamed Franklin Templeton, Inc.
  • Client accounts hold economic interest: The filing discloses that clients of the Investment Management Subsidiaries, including registered investment companies and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and proceeds from the sale of, the reported securities.
  • Shared power: No shared voting or dispositive power was reported by any of the four reporting persons.

Franklin Advisers Holds All Voting and Dispositive Control Over Contineum Therapeutics Position

According to the Schedule 13G Amendment No. 4 filed on October 26, 2026, four reporting persons are named: Franklin Templeton, Inc. (incorporated in Delaware), Charles B. Johnson (United States), Rupert H. Johnson, Jr. (United States), and Franklin Advisers, Inc. (incorporated in California). All four share a principal business address of One Franklin Parkway, San Mateo, CA 94403-1906. The issuer, Contineum Therapeutics, Inc., is headquartered at 3565 General Atomics Court, Suite 200, San Diego, CA 92121, according to the filing.

The filing makes clear that while Franklin Templeton, Inc. reports an aggregate beneficial ownership of 1,704,550 shares, representing 5.2% of Contineum Therapeutics' Class A Common Stock (CUSIP 21217B100, $0.001 par value per share), the actual sole voting power and sole dispositive power over all 1,704,550 shares rests entirely with Franklin Advisers, Inc. as a subsidiary. Charles B. Johnson and Rupert H. Johnson, Jr. each report 0.00 shares of beneficial ownership and 0% of the class. The filing notes that Franklin Resources, Inc. was renamed Franklin Templeton, Inc. effective August 17, 2026.

Regarding who holds the underlying economic interest, the filing states that "the clients of the Investment Management Subsidiaries, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein." The filing was signed by Thomas C. Mandia, in his capacity as Assistant Secretary of Franklin Templeton, Inc. and Franklin Advisers, Inc., and as attorney-in-fact for Charles B. Johnson and Rupert H. Johnson, Jr.

What Was Disclosed

Franklin Templeton, Inc. and three related persons filed Amendment No. 4 to Schedule 13G covering 1,704,550 shares of Contineum Therapeutics Class A Common Stock, equal to 5.2% of the class, with the triggering event dated September 30, 2026.